Amylyx Pharmaceuticals Inc

AMLX

Equity

ISIN null / Valor 115580129

NASDAQ (2026-07-01)

USD 17.95-0.06%

Amylyx Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Amylyx Pharmaceuticals is a publicly traded biotechnology company (Nasdaq: AMLX) that develops therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and related central nervous system disorders. Its lead product, AMX0035 — marketed in the U.S. as Relyvrio — is an oral fixed‑dose combination of sodium phenylbutyrate and taurursodiol that completed late‑stage clinical testing for ALS and received U.S. regulatory approval; the company is commercializing that therapy while conducting additional clinical studies and pursuing regulatory filings in other jurisdictions. Amylyx’s operations are centered on research and development of small‑molecule combinations intended to target cellular stress and neurodegeneration pathways, together with the clinical development, regulatory engagement and commercialization activities required to advance its pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

180%1Y

-16.8%3Y

%5Y

Performance

65.2%1Y

123%3Y

117%5Y

Volatility